101 related articles for article (PubMed ID: 23268013)
61. Usefulness of Serum Anti-p53 Antibody Measurement in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
Kojima K; Shindoh J; Akabane M; Umino R; Kobayashi Y; Okubo S; Hashimoto M
World J Surg; 2021 Jun; 45(6):1906-1912. PubMed ID: 33721071
[TBL] [Abstract][Full Text] [Related]
62. Serum p53 antibody in breast cancer.
Yamamoto S; Chishima T; Adachi S; Harada F; Toda Y; Arioka H; Hasegawa N; Kakuta Y
Cancer Biomark; 2014; 14(4):203-6. PubMed ID: 24934362
[TBL] [Abstract][Full Text] [Related]
63. Circulating antibodies to carcinoembryonic antigen related to improved recurrence-free survival of patients with colorectal carcinoma.
Wu XJ; Fang YJ; Lin JZ; Lu ZH; Li LR; Chen G; Ding PR; Kong LH; Pan ZZ; Wan DS
J Int Med Res; 2011; 39(3):838-45. PubMed ID: 21819716
[TBL] [Abstract][Full Text] [Related]
64. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients.
Tang R; Ko MC; Wang JY; Changchien CR; Chen HH; Chen JS; Hsu KC; Chiang JM; Hsieh LL
Int J Cancer; 2001 Dec; 94(6):859-63. PubMed ID: 11745489
[TBL] [Abstract][Full Text] [Related]
65. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
[TBL] [Abstract][Full Text] [Related]
66. [Clinical Significance of Serum p53 Antibody Measurement in Colorectal Cancer Patients].
Yokomizo H; Yoshimatsu K; Yano Y; Okayama S; Sakuma A; Satake M; Yamada Y; Matsumoto A; Fujimoto T; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Kato H; Naritaka Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1301-1303. PubMed ID: 27760967
[TBL] [Abstract][Full Text] [Related]
67. [The value of serum human tumor protein P53 in colorectal cancer combined diagnosis and postoperative monitoring].
Fan P; Zhang Y; Deng F; Chen SH; Li M; Zhang Q
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2670-2673. PubMed ID: 28910954
[No Abstract] [Full Text] [Related]
68. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer.
Pellegrini P; Contasta I; Berghella AM; Gargano E; Mammarella C; Adorno D
Cancer Immunol Immunother; 2000 Sep; 49(7):388-94. PubMed ID: 10999465
[TBL] [Abstract][Full Text] [Related]
69. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection.
Takeda A; Shimada H; Nakajima K; Yoshimura S; Suzuki T; Asano T; Ochiai T; Isono K
Int J Clin Oncol; 2001 Feb; 6(1):45-9. PubMed ID: 11706527
[TBL] [Abstract][Full Text] [Related]
70. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
[TBL] [Abstract][Full Text] [Related]
71. [Value of serum P53 antibody as a tumor marker surveillance of colorectal cancer within follow-up after curative resection].
Shou CC; Huang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Oct; 15(10):1020-2. PubMed ID: 23297459
[TBL] [Abstract][Full Text] [Related]
72. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue.
Broll R; Duchrow M; Oevermann E; Wellm C; Schwandner O; Schimmelpenning H; Roblick UJ; Bruch HP; Windhövel U
Int J Colorectal Dis; 2001 Feb; 16(1):22-7. PubMed ID: 11317693
[TBL] [Abstract][Full Text] [Related]
73. Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer.
Teras LR; Gapstur SM; Maliniak ML; Jacobs EJ; Gansler T; Michel A; Pawlita M; Waterboer T; Campbell PT
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):219-223. PubMed ID: 29254936
[No Abstract] [Full Text] [Related]
74. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.
Kressner U; Glimelius B; Bergström R; Påhlman L; Larsson A; Lindmark G
Br J Cancer; 1998 Jun; 77(11):1848-51. PubMed ID: 9667657
[TBL] [Abstract][Full Text] [Related]
75. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer.
Suzuki T; Shimada H; Ushigome M; Koike J; Funahashi K; Nemoto T; Kaneko H
Clin J Gastroenterol; 2016 Apr; 9(2):55-8. PubMed ID: 26919859
[TBL] [Abstract][Full Text] [Related]
76. [Serum p53 antibody assay: evaluation in colorectal cancer].
Hammel P; Soussi T
Rev Med Interne; 2000 Feb; 21(2):167-73. PubMed ID: 10703073
[TBL] [Abstract][Full Text] [Related]
77. Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer.
Kumamoto K; Ishida H; Kuwabara K; Amano K; Chika N; Okada N; Ohsawa T; Kumagai Y; Ishibashi K
Mol Clin Oncol; 2017 Oct; 7(4):595-600. PubMed ID: 28855992
[TBL] [Abstract][Full Text] [Related]
78. Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors.
Shibata Y; Kotanagi H; Andoh H; Koyama K; Itoh H; Kudo S
Dis Colon Rectum; 1996 Nov; 39(11):1269-74. PubMed ID: 8918437
[TBL] [Abstract][Full Text] [Related]
79. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer.
van der Burg SH; de Cock K; Menon AG; Franken KL; Palmen M; Redeker A; Drijfhout J; Kuppen PJ; van de Velde C; Erdile L; Tollenaar RA; Melief CJ; Offringa R
Eur J Immunol; 2001 Jan; 31(1):146-55. PubMed ID: 11169448
[TBL] [Abstract][Full Text] [Related]
80. Serum anti-p53 antibody as a tumour marker for colorectal cancer screening.
Iwamuro M; Kawai Y; Matsumoto T; Uda M; Okada H
Ecancermedicalscience; 2015; 9():560. PubMed ID: 26284124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
